Longeveron Inc. LGVN
- Market cap
- $9.1M
- P/E
- 0.0×
Follow LGVN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 284.00 | 280.00 | 115.00 | 7.71 | 4.92 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 4,500.00 | 1,677.00 | 457.90 | 143.00 | 22.40 |
High Price
|
|||
| — | — | — | 12 | 12 | 22 | 21 | 24 | 26 | 38 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 2 | 6 | 6 | 1 | 1 | 1 | 2 | 1 |
Revenue
|
|||
| — | — | 31.88% | 31.10% | 32.44% | 45.18% | 40.67% | 31.17% | 78.76% | 66.97% |
Gross Margin
|
|||
| — | — | (6) | (3) | (4) | (17) | (19) | (21) | (16) | (23) |
EBT
|
|||
| — | — | (296.83%) | (52.49%) | (66.10%) | (1,305.13%) | (1,541.33%) | (3,020.17%) | (667.77%) | (1,893.58%) |
EBT Margin
|
|||
| — | 0 | (6) | (3) | (4) | (17) | (19) | (21) | (16) | (23) |
Net Income
|
|||
| — | — | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| — | — | 0.11 | 0.30 | 35.14 | 6.90 | 5.83 | 3.26 | 2.54 | 0.68 |
Revenue/Sh
|
|||
| — | — | (0.33) | (0.15) | (23.20) | (90.00) | (90.00) | (102.00) | (26.20) | (12.90) |
Earnings/Sh
|
|||
| — | — | (0.27) | (0.13) | (14.76) | (50.93) | (66.61) | (87.45) | (14.74) | (10.61) |
Cash Flow/Sh
|
|||
| — | — | 0.00 | (0.01) | (1.63) | (6.47) | (4.08) | (3.19) | (1.05) | (0.34) |
Capex/Sh
|
|||
| — | — | (0.27) | (0.13) | (16.39) | (57.40) | (70.70) | (90.64) | (15.79) | (10.95) |
Free CF/Sh
|
|||
| — | — | 0.36 | 0.23 | 12.22 | 197.95 | 97.77 | 31.02 | 23.26 | 3.23 |
Book Value/Sh
|
|||
| — | — | 19 | 19 | 0 | 0 | 0 | 0 | 1 | 2 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 21.09 | 21.09 | 21.09 | 174.86 | 57.83 | 40.46 | 6.81 | 7.42 |
PS Ratio
|
|||
| — | — | 60.66 | 60.66 | 60.66 | 6.10 | 3.45 | 4.26 | 0.74 | 1.57 |
PB Ratio
|
|||
| — | — | 21.02 | 21.02 | 21.02 | 150.43 | 43.88 | 35.76 | (0.64) | 4.16 |
EV/Sales
|
|||
| — | — | (45.07) | (45.07) | (45.07) | (18.00) | (3.62) | (1.29) | 0.10 | (0.26) |
EV/FCF
|
|||
| — | — | (5) | (2) | (2) | (10) | (14) | (19) | (14) | (19) |
Op' Cash Flow
|
|||
| — | — | 0 | 0 | 0 | (1) | (1) | (1) | (1) | (1) |
Capex
|
|||
| — | — | (5) | (3) | (3) | (11) | (15) | (20) | (15) | (19) |
FCF
|
|||
| — | — | 2 | 0 | (2) | 33 | 15 | 2 | 17 | 1 |
Working Cap'
|
|||
| — | — | — | 4 | 0 | 3 | 3 | 1 | 1 | 0 |
Total Debt
|
|||
| — | — | (4) | 2 | 0 | (32) | (17) | (4) | (18) | (4) |
Net Debt
|
|||
| — | — | 7 | 4 | 2 | 37 | 21 | 7 | 22 | 6 |
Sh' Equity
|
|||
| — | — | (120.45%) | (28.05%) | (37.54%) | (65.55%) | (53.68%) | (112.49%) | (130.85%) | (126.77%) |
ROA
|
|||
| — | — | 0.00% | (27.89%) | (148.41%) | (196.51%) | (326.87%) | (464.75%) | (296.82%) | (1,230.29%) |
ROIC
|
|||
| — | — | (112.56%) | (52.58%) | (116.24%) | (86.50%) | (65.00%) | (163.05%) | (172.02%) | (164.75%) |
ROE
|
|||
Longeveron Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FBLG FibroBiologics Inc. | $9.1M | 0.0× | Compare |
| LNAI Lunai Bioworks Inc. | $8.8M | 0.0× | Compare |
| ALZN Alzamend Neuro, Inc. | $8.8M | 0.0× | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IMRN IMMURON | $9.6M | 0.0× | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $9.7M | 0.0× | Compare |
| CSCIF COSCIENS Biopharma Inc. | $8.6M | 1.0× | Compare |
| APRE Aprea Therapeutics, Inc. | $9.8M | 0.0× | Compare |
Longeveron Inc. (LGVN) key facts
- Longeveron Inc. (LGVN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024.
- As of September 25, 2026, LGVN traded at $2.81, a market capitalization of $9.1 million.
- Return on equity was −164.8% and debt-to-equity 0.00.
Longeveron Inc. (LGVN) Latest News
22 Sep
Longeveron’s ELPIS II trial in 40 infants with hypoplastic left heart syndrome missed its primary endpoint: change in right ventricular ejection fraction at 12 months, with an estimated difference of −0.7 percentage points (p=0.8336). The company launched a strategic review, intends to hire an investment bank, and plans cash-conservation measures to preserve value while pursuing a viable development or partnership path. Positive notes include no new safety signals and continued interest in the aging-related frailty program, which could support licensing discussions. Risks center on regulatory uncertainty, lack of efficacy signals, and the need for funding; cash, runway into late 2026 remains unclear, making upfront funding, retained rights, and future obligations critical in any deal. Failure to meet the primary endpoint with an unclear runway and a strategic review create a moderate, balanced impact on future value.
17 Sep
Longeveron Inc. (LGVN) reported disappointing clinical trial results. Disappointing trial results signal major setbacks for Longeveron Inc.'s clinical programs and future prospects.
16 Sep
Longeveron releases topline results from ELPIS II Phase 2b trial of laromestrocel in hypoplastic left heart syndrome. Phase 2b trial data for lead candidate can shift valuation and development timeline.
19 Aug
Longeveron (LGVN) Q2 2026 earnings call transcript covers quarterly financial results, operational updates, and forward outlook. Quarterly earnings call delivers financial and strategic updates that moderately influence near-term market sentiment and valuation.
13 Aug
Longeveron Inc. (LGVN) reaches a major inflection point with developments that could reshape its trajectory. Major inflection point indicates strategic shifts likely to alter company performance and sentiment.
12 Aug
Longeveron Inc. released its Q2 2026 earnings call summary detailing financial results, operational updates, and strategic outlook. Quarterly earnings summaries deliver financial metrics and guidance that can shift near-term investor sentiment and valuation.
Longeveron Inc. (LGVN) reported second quarter 2026 financial results and issued a business update. Quarterly financial results and business updates can shift near-term investor views on company performance.
11 Aug
Longeveron Inc. has been named a finalist team in the XPRIZE Healthspan Global Competition and will receive a $1,000,000 Milestone 2 Award. The $1 million award and finalist status provides major validation and non-dilutive capital that can accelerate Longeveron's clinical programs and improve market perception.
13 Jul
Longeveron announces presentation of clinical data at the 2026 AAIC indicating laromestrocel reduced neuroinflammation in Alzheimer's disease patients. Positive clinical data on laromestrocel for Alzheimer's signals potential progress in product development and future market opportunities.
9 Jun
Longeveron Inc. (LGVN) has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA). SME status grants Longeveron regulatory and fee benefits in Europe that may support development efforts but stops short of major approvals or revenue impact.
20 May
Longeveron Inc. issued a letter to stockholders outlining its corporate strategy, strategic partnering approach, and key priorities for 2026. Stockholder letter on strategy and 2026 priorities may moderately shape investor views and company trajectory without immediate major operational shifts.
14 May
Longeveron Inc. (LGVN) released Q1 2026 earnings call summary covering quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings disclosure includes financial performance and strategic insights that could significantly sway investor sentiment and company trajectory.
Longeveron Inc. (LGVN) positions for success in 2026 through advancing clinical trials, positive data readouts, and strategic partnerships in regenerative medicine targeting Alzheimer's and aging frailty. Optimistic 2026 outlook highlights major clinical and strategic advancements poised to significantly boost LGVN's trajectory and investor sentiment.
13 May
Longeveron Inc. (LGVN) released the transcript of its Q1 2026 earnings call, detailing financial results, operational updates, and forward-looking guidance. Q1 2026 earnings transcript covers financial performance, pipeline progress, and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.
Longeveron Inc. (LGVN) Q1 2026 earnings call complete transcript released, detailing quarterly financial results, operational updates, and management commentary. Q1 2026 earnings call discloses financial performance, guidance, and strategic developments that significantly influence investor sentiment and stock trajectory.
Longeveron Inc. (LGVN) announced first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates moderately impact financial performance and investor sentiment for clinical-stage biotechs like LGVN.
11 May
Longeveron Inc. (LGVN) announces positive review from Independent Data Monitoring Committee for its Phase 2b stem cell therapy clinical trial in Hypoplastic Left Heart Syndrome (HLHS), recommending completion of enrollment and the study. Positive Phase 2b DMC review signals trial success potential, significantly advancing Longeveron's pipeline and likely boosting investor sentiment.
8 May
Longeveron announces constructive Type C meeting with U.S. FDA ahead of data readout for ELPIS II Phase 2b clinical trial evaluating treatment for Hypoplastic Left Heart Syndrome (HLHS). Constructive FDA meeting ahead of Phase 2b data readout provides regulatory clarity and boosts prospects for HLHS treatment advancement, significantly impacting stock and trajectory.
8 Apr
Longeveron Inc. (LGVN) received a Chinese patent for potency assay methods to evaluate human mesenchymal stem cells (MSCs), bolstering its intellectual property for stem cell therapies. Chinese patent grant fortifies Longeveron's IP in a major market, supporting MSC therapy advancement and potential global expansion.
18 Mar
Longeveron Inc. (LGVN) released Q4 2025 earnings call transcript detailing financial results, operational updates, and future guidance. Q4 2025 earnings transcript discloses key financials, pipeline progress, and strategic outlook significantly influencing LGVN's trajectory and investor sentiment.
Longeveron Inc. (LGVN) Q4 2025 earnings call summary details quarterly financial results, operational progress, and forward-looking guidance. Q4 earnings summary discloses critical financials, pipeline updates, and strategic outlook directly impacting LGVN's valuation and investor confidence.
Longeveron Inc. (LGVN) faces 2026 as a critical pivot point, with key milestones in clinical trials, funding, and commercialization determining its survival and growth trajectory amid cash constraints and regulatory hurdles. 2026 serves as a critical pivot point with major clinical, funding, and regulatory events poised to significantly alter LGVN's trajectory and investor sentiment.
17 Mar
Longeveron Inc. (LGVN) announced full-year 2025 financial results and provided a business update. Full-year financial results and business updates significantly influence investor sentiment and stock trajectory.
16 Mar
Longeveron Inc. (LGVN) reports Q4 2025 earnings results, flagged as key earnings to watch. Q4 2025 earnings disclosure reveals critical financial performance metrics influencing Longeveron Inc.'s trajectory and investor sentiment.
11 Mar
Longeveron Inc. (LGVN) closed a private placement of up to $30 million. Raising up to $30 million via private placement provides substantial funding to support clinical trials and operations, significantly enhancing financial position and investor sentiment.
Longeveron Inc. (LGVN), a penny stock, offers a $30 million reason to buy today, highlighting major positive developments poised to drive significant growth. $30 million funding or milestone significantly boosts Longeveron's trajectory as a small biotech penny stock.
10 Mar
Longeveron Inc. (LGVN) announces private placement of up to $30 million to fund ongoing operations and clinical development programs. Private placement raises up to $30 million, providing critical funding for clinical trials and operations in a cash-strapped biotech.
Longeveron Inc. (LGVN) secures operations after successfully passing a crucial test. Passing a crucial test secures LGVN's operations, enabling major strategic continuity and boosting investor sentiment.
26 Feb
Longeveron Inc. (LGVN) reports continued impressive results from clinical trials, highlighting strong efficacy and safety data that bolster the company's regenerative medicine pipeline. Ongoing impressive trial results represent a major milestone likely to enhance LGVN's competitive position, accelerate regulatory progress, and drive substantial investor interest.
25 Feb
Longeveron published Phase 2b clinical trial results in Cell Stem Cell demonstrating its stem cell therapy improved conditions in patients with age-related frailty. Positive Phase 2b results in a prestigious journal like Cell Stem Cell validate Longeveron's lead therapy for frailty, positioning it for Phase 3 trials, partnerships, and transformative market gains.